Flt3/MerTK Inhibitor MRX-2843 for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Emory University Hospital/Winship Cancer Institute, Atlanta, GANon-Small Cell Lung Cancer+4 MoreFlt3/MerTK Inhibitor MRX-2843 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a combination of drugs to see if they are effective in treating patients with lung cancer that has spread to other parts of the body. The drugs may work by blocking enzymes needed for cell growth.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Stage IV Lung Cancer
  • Stage IVA Lung Cancer
  • Stage IVB Lung Cancer
  • Non-Small Cell Lung Cancer (NSCLC)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: From start of treatment to time of progression or death, whichever occurs first, assessed at 1 year

Year 5
Overall response rate (ORR) (dose expansion)
Year 1
1-year progression free survival rate (dose expansion)
Year 5
Maximum tolerated dose (MTD)
Predictive Protein Biomarkers
Recommended phase 2 dose (RP2D) of the tested combination (dose escalation)

Trial Safety

Trial Design

1 Treatment Group

Treatment (osimertinib, MRX-2843)
1 of 1

Experimental Treatment

69 Total Participants · 1 Treatment Group

Primary Treatment: Flt3/MerTK Inhibitor MRX-2843 · No Placebo Group · Phase 1

Treatment (osimertinib, MRX-2843)Experimental Group · 2 Interventions: Osimertinib, Flt3/MerTK Inhibitor MRX-2843 · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Osimertinib
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from start of treatment to time of progression or death, whichever occurs first, assessed at 1 year

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,527 Previous Clinical Trials
2,714,462 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,161 Previous Clinical Trials
41,167,314 Total Patients Enrolled
Taofeek K Owonikoko, MD, PhDPrincipal InvestigatorEmory University
Suresh Ramalingam, MDPrincipal InvestigatorEmory University
5 Previous Clinical Trials
1,649 Total Patients Enrolled
Conor Steuer, MDPrincipal InvestigatorEmory University
1 Previous Clinical Trials
50 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 19 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You can safely swallow pills or tablets.

Frequently Asked Questions

Are there still vacancies for patients to join this experiment?

"As indicated on the clinicaltrials.gov database, this trial is actively enrolling participants and was first introduced to the public on February 24th 2021 with its most recent update occuring on March 8th 2022." - Anonymous Online Contributor

Unverified Answer

What evidence is there to support the efficacy of Flt3/MerTK Inhibitor MRX-2843?

"Currently, 101 investigations into Flt3/MerTK Inhibitor MRX-2843 are taking place with 17 trials in the final stage. Out of Uniondale, New York several studies on this subject matter have been initiated and a grand total of 4702 locations are running clinical trials for Flt3/MerTK Inhibitor MRX-2843." - Anonymous Online Contributor

Unverified Answer

Is this a pioneering research project?

"Since 2013, research into Flt3/MerTK Inhibitor MRX-2843 has been ongoing. It was initially sponsored by AstraZeneca in a study involving 603 patients. Following the first trial, it received its Phase 1 & 2 drug approval and is now currently being studied across 1059 cities within 51 nations with 101 active trials." - Anonymous Online Contributor

Unverified Answer

How many volunteers have participated in this experiment?

"Affirmative. The clinical trial is currently recruiting, as evidenced by the data hosted on clinicaltrials.gov from its inception date of February 24th 2021 and latest update on March 8th 2022. 69 volunteers are being sought across a single site for recruitment." - Anonymous Online Contributor

Unverified Answer

Could you please expound on the risks of Flt3/MerTK Inhibitor MRX-2843?

"Assessing the safety of Flt3/MerTK Inhibitor MRX-2843 on a scale from 1 to 3, our team at Power have assigned it a score of 1 as this is still in its early Phase 1 trial and there is limited evidence regarding efficacy and safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.